Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.44 |
| ▸ | MME | P08473 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31665987 | 1.00 | GNPAT (0.50) | GNPATCA2CA4ENPEPMME | |
| SCHEMBL29886936 | 1.00 | GNPAT (0.50) | GNPATCA2CA4ENPEPMME | |
| SCHEMBL434311 | 1.00 | GNPAT (0.50) | GNPATCA2CA4ENPEPMME | |
| SCHEMBL31665968 | 1.00 | GNPAT (0.50) | GNPATCA2CA4ENPEPMME | |
| SCHEMBL31666010 | 1.00 | GNPAT (0.50) | GNPATCA2CA4ENPEPMME | |
| SCHEMBL31666032 | 1.00 | GNPAT (0.50) | GNPATCA2CA4ENPEPMME | |
| SCHEMBL23366194 | 1.00 | GNPAT (0.50) | GNPATCA2CA4ENPEPMME | |
| SCHEMBL13059958 | 1.00 | GNPAT (0.50) | GNPATCA2CA4ENPEPMME | |
| SCHEMBL22070155 | 1.00 | GNPAT (0.50) | GNPATCA2CA4ENPEPMME | |
| SCHEMBL29886778 | 1.00 | GNPAT (0.50) | GNPATCA2CA4ENPEPMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250123280-A1 | LABEL-FREE DETECTION OF PROTEASE ACTIVITY | UNIV OREGON HEALTH & SCIENCE (US) | 2025-04-17 | — | — | US | claimed |
| WO-2023003984-A2 | LABEL-FREE DETECTION OF PROTEASE ACTIVITY | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2023-01-26 | — | — | WO | claimed |
| WO-2012010851-A1 | CAPILLARY ELECTROPHORESIS OF CARBOHYDRATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-01-26 | — | — | WO | claimed |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250345411-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | CureVac SE (DE) | 2025-11-13 | — | — | US | disclosed |
| EP-3183365-B1 | REUSABLE INITIATORS FOR SYNTHESIZING NUCLEIC ACIDS | MOLECULAR ASSEMBLIES INC (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-4608455-A1 | SELF-ASSEMBLING NANOPARTICLES | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608437-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12390520-B2 | Vaccination in newborns and infants | Cure Vac SE (DE) | 2025-08-19 | — | — | US | disclosed |
| EP-4087944-A1 | SOLID-PHASE POLYMER SYNTHESIS ON REUSABLE SUBSTRATES | Microsoft Technology Licensing, LLC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-20220322709-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | ALMENDRA PTE LTD (SG) | 2022-10-13 | — | — | US | disclosed |
| WO-2022208443-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | ALMENDRA PTE. LTD. (SG) | 2022-10-06 | — | — | WO | disclosed |
| US-20220264924-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | ALMENDRA PTE. LTD. (SG) | 2022-08-25 | — | — | US | disclosed |
| WO-2022177993-A1 | SELF-ASSEMBLING NANOPARTICLES BASED ON AMPHIPHILIC PEPTIDES | VACCITECH NORTH AMERICA, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-11384377-B2 | Reusable initiators for synthesizing nucleic acids | Molecular Assemblies, Inc. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-4009810-A1 | METHODS AND COMPOSITIONS FOR IMPROVED TASTE QUALITY | Almendra Pte. Ltd. (SG) | 2022-06-15 | — | — | EP | disclosed |
| US-11331643-B2 | Reusable initiators for synthesizing nucleic acids | Molecular Assemblies, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| WO-2012010851-A1 | CAPILLARY ELECTROPHORESIS OF CARBOHYDRATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | GNPAT 4882/4885CA2 1580/4885CA4 2130/4885 |
| US-20250345410-A1 | VACCINATION IN NEWBORNS AND INFANTS | HLA-DRB1, TLR3, TLR9 | GNPAT 1583/4885CA2 3148/4885CA4 3089/4885 |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | GNPAT 1815/4885CA2 3091/4885CA4 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.